Bendamustine Clinical Trial / Breast Screening by MRI / Advantages

Tower Cancer Research Foundation
SEPTEMBER 2008
A
Promising Cancer Drug Emerges
From Behind The Iron Curtain
chemotherapeutic agent known as
bendamustine was developed in East
Germany in 1963 and first used there
in 1969 for the treatment of multiple
myeloma.
Eventually, more than
20,000 patients with a variety of
malignancies were treated with this
drug (especially lymphoma, myeloma,
and chronic lymphocytic leukemia).
Despite widespread use and successes,
the Iron Curtain was in place and there
was essentially no scientific exchange
between East and West Germany.
With the fall of the Berlin Wall in 1989
and the gradual blending of science
between the former East and West
German
medical
communities,
bendamustine emerged from the
shadows and was identified as a
potentially very important agent.
However, as information about this
drug became known in other parts of
Europe and the US it was evident that
the data acquired in the former
East Germany did not satisfy
rigorous statistical standards. Before
bendamustine could be accepted and
marketed in the US, clinical trials had
to be repeated and the data confirmed.
During the past few years the drug has
been tested in several controlled Phase
II and III trials. The most important
thus far was an international,
multicenter Phase III study of 301
C
O
N
T
E
N
T
S
previously untreated patients with
chronic lymphocytic leukemia (CLL),
comparing bendamustine to the single
agent standard of care. Responses
nearly doubled with bendamustine,
and almost one-third of patients had a
complete regression of their disease, as
A Portion of the Berlin Wall Left Standing
(c. 1995) Courtesy of David Rosenbaum, MD
compared to 2% treated with standard
drug therapy. In March of 2008, the
FDA approved bendamustine for
treatment of CLL in the US under the
name TREANDA®.
Impressive
results also have been reported in
studies of lymphoma patients who had
become resistant to standard therapy.
When bendamustine was given as a
single “rescue” agent to those
individuals resistant to rituximab (a
Drug Emerges From Behind the Iron Curtain............1
Breast Screening by MRI ............................................2
Dr. Peter Lee Joins TCRF..............................................3
Ronnie Lippin Cancer Information & Resource Line...3
Altruist Enrolls on a Trial.............................................4
Leukemia Awareness Month..........................................4
Advantages of Clinical Trial Participation...................5
commonly administered monoclonal
antibody), 77% responded positively.
For lymphoma patients not yet
resistant to rituximab, bendamustine
given together with this antibody
resulted in a 92% response rate. In
addition, this drug currently is being
tested in other malignancies such as
multiple myeloma, sarcoma, and breast
cancer, since preliminary data have
indicated positive responses in these
diseases.
Thus far, the potential of bendamustine
as initially described in East German
medical publications has been
validated by contemporary European
and US studies.
Tower Cancer
Research Foundation is a participating
site for an important Phase II study of
this drug as part of a triple therapy
regimen.
We are offering this
promising agent to lymphoma patients
unresponsive to standard treatment, or
having
relapsed
after
initially
responding to treatment. Hopefully,
this will be a major breakthrough
regimen for these patients. TCRF also
is planning to open a similar trial for
newly diagnosed and untreated
lymphoma patients to assess response
rates when the drug is administered
right at the outset of their disease,
rather than after heavy prior
treatment.
Frank E. Rosenfelt Drug Development Program............5
Foundation News...........................................................6
Notes from the Chairman of the Board...........................6
Going Green...................................................................6
2008 Spirit of Hope Luncheon......................................7
Tree of Life....................................................................8
Board of Directors..........................................................8
W
h i c h Wo m e n N e e d B r e a s t S c r e e n i n g B y M R I ?
David L. Rosenbaum, MD - Director of Medical Education
At present, mass screening by mammography is the only imaging procedure proven statistically in controlled trials to decrease
mortality rates from breast cancer. However, MRI imaging is the
technique with the highest sensitivity for detecting abnormalities
within the breast, causing experts to discuss its potential use for
routine breast cancer screening. Due to certain important limitations, MRI has not been approved for mass population screening. The first limitation is cost, as this procedure is quite expensive. Another is the lack of procedure standardization. Equipment and techniques may vary widely from place to place
thereby limiting accurate interpretation. Further, MRI of the
breast is relatively new and the methodology is changing rapidly.
In this regard, truly expert radiologist-readers are found at sites
with high procedure volumes, while radiologists at low volume
sites are still on a learning curve.
Breast MRI
Courtesy of:
Dr. Steven Harmes
Baylor UMC
Perhaps the most significant and controversial problem with
breast MRI is that, in a sense, it may be too sensitive. In women
with normal breasts and no risk factors it may detect
abnormalities that are unimportant. However, once these are
identified, patients may have to undergo additional testing,
biopsies, and even more extensive surgery just to prove that the
findings were not cancer. In medical terms this is called a “lack
of specificity”, which can frequently lead to unnecessary procedures.
• Prior radiation to the chest between ages 10 and 30:
These individuals, many of whom have been treated for
Hodgkin’s Lymphoma, have a markedly increased risk for
breast cancer later in life.
Nonetheless, it is undeniable that the increased sensitivity of
MRI is an important adjunct to mammography screening in
women with high risk situations. The American Cancer Society
recognized this when it issued 2007 guidelines that defined high
risk individuals and recommended annual MRI screening for
women in the following settings:
• Newly diagnosed breast cancer: There is evidence
that MRI may detect tumors in the opposite breast in a
small percentage, and/or within the same breast, missed
by mammograms. This also occurs in certain specific and
unusual types of breast cancer. Further, MRI may be
useful to determine the precise extent of cancer in order to
facilitate better surgical planning.
• BRCA breast cancer gene mutations, and/or a very
strong family history: Carriers of BRCA mutations not
only have an extremely high lifetime risk (up to 80%), but
their cancers may have a benign appearance by mammography. A strong family history might be defined as a first
degree relative (parent, sibling, or child) developing breast
cancer before menopause, two or more first or second
degree relatives with breast (or ovarian) cancer, two
2
Cancer
cancers (breast or ovarian) in the same close relative, and
male breast cancer in a first degree relative. Even with no
identifiable mutation, individuals with these strong family
histories are sufficiently at increased risk to consider an
annual MRI possibly starting at an age as young as 30.
• Breast reconstruction: Silicone leaks can mimic cancer
on mammograms, whereas MRI is valuable in differentiating
silicone changes from malignancy.
• Inconclusive breast imaging: Mammography can be
exceedingly difficult to interpret in women with dense
breasts or other anatomical variations, including prior breast
surgery with scarring.
Therefore, sufficient evidence exists to recommend routine MRI
screening in high risk patients (defined as greater than 20-25%
lifetime risk for breast cancer) as well as for those with anatomic
situations that cause mammography to be technically unsatisfactory. Of course patients must be able to lie prone and still in the
unit for 30-45 minutes, will receive dye, and cannot have a pacemaker or metal anywhere near the breasts.
Routine breast MRI screening of high risk women detects 4 to 5
cancers per 100 examinations that otherwise would have been
missed by routine mammography. These figures do not apply to
women at normal risk, and to date there are no data to support
routine mass screening of the general population. There are
gray areas, however, such as women with dense breast tissue,
non-cancerous but abnormal prior breast biopsies, and a previous personal history of breast cancer. The American Cancer
Society finds insufficient evidence to recommend for or against
MRI screening in these situations, which must be decided on a
case by case basis.
Dr. Peter Lee Joins TCRF
Tower Cancer Research Foundation is proud to
announce that Dr. Peter Lee has been appointed Associate Medical Director He will join Dr. Peter Rosen in
expanding our Foundation’s portfolio of clinical trials,
especially in the exciting area of early phase studies. He
looks forward to participating in developing programs
for new treatments as well as the direct patient care of
subjects enrolled in our studies.
Dr. Lee was born in Hong Kong but was primarily
educated in the US since nine years of age. He
graduated from the University of California at Berkeley
and then returned to Hong Kong in 1986 where he subsequently obtained a Ph.D in physiology. He returned to
the US in 1992 and received his medical degree and
performed internship and residency training at Jefferson
Medical College and University Hospital in Philadelphia. Between 1999 and 2002 Dr. Lee was a fellow in
the Hematology-Oncology program at UCLA. Upon
completion of his fellowship he accepted a faculty position as Assistant Clinical Professor at UCLA where he
remained until 2005. During that year he decided to
leave academia to assume a position as a Clinical
Research Director at Amgen Pharmaceutical.
At Amgen his responsibilities included designing clinical trials, data analysis, and interacting with various
regulatory agencies, especially the FDA. These are the
exact skills that he will be exercising at TCRF, but in
addition, he looks forward to having much more contact
with patients. Dr. Lee’s background and training are
perfectly suited to his new position as Associate Medical
Director and he is certain to be an important asset to our
Foundation.
Ronnie Lippin Cancer Information & Resource Line
a t To w e r C a n c e r R e s e a r c h F o u n d a t i o n
Launches October 13th 2008
We are very excited to announce the beginning of a free cancer information and resource service for the Los
Angeles community. Beginning October 13th, anyone in Los Angeles will be able to obtain free personalized
cancer related information and resource referrals. Our trained professional staff will be available by phone or
email to help direct cancer patients and their families through the often confusing world of cancer issues and
resources. We can help find solutions to issues such as transportation needs, prescription drug assistance
programs, attendant care and home health care agency referrals, food and nutrition programs, and more.
Partially funded through the generosity of Dick Lippin and his daughter Alexandra in memory of their late wife
and mother, Ronnie, the goal of this service is to relieve the burden and challenges of a cancer diagnosis by
providing information and professional assistance sorting through the options and decisions that can be so
overwhelming for a newly diagnosed cancer patient.
Beginning on October 13th, this free community service can be accessed by calling
1-877-RLC-2120 (1-877-752-2120)
or by visiting our website, www.LACancerInfo.org
3
A True Altruist Enrolls in a Clinical Trial
antiestrogen. Both cancers were cured
by decisive medical action.
Lucy S. found her unusual blood
disease to be much different and more
frustrating than the two cancers she
had dealt with previously. In 1980,
she was cured of thyroid cancer after
extensive neck surgery; in the same
year her husband, an Air Force colonel, died suddenly. In 1986 she was
shocked to find that she had breast
cancer, which was treated successfully with surgery, radiation, and an
However, this blood disease, called
myelodysplastic syndrome (MDS), was
different. It started two years ago when
she was 84. It seemed simple enough
at first. Anemia was the main symptom,
and it was handled easily enough with
shots. Although the MDS dragged on
and on, it did not interfere at all with her
lifestyle, which included going to the
gym regularly, walking 4 to 5 miles and
doing 50 sit-ups daily, as well as taking
care of her home. Also, she was especially close to her three sons and their
families.
In December, 2007, there was a sudden
change in her blood count. Another
bone marrow procedure was performed,
which showed that her mild blood
disease had abruptly and unexpectedly
undergone a transformation into acute
September is Leukemia Awareness Month
Although all cases of leukemia originate in the bone marrow, the four major types vary widely in
signs, symptoms and ultimate outcomes. Essentially, each type is an entirely different disease
having in common only the term “leukemia” and the presence of malignant cells in the bone
marrow.
About 39,000 new cases of leukemia are expected to be diagnosed in the US this year. The
estimated 2008 incidence and survival rates vary widely according to type. Childhood acute
lymphocytic leukemia (ALL) is cured in the majority of cases, while adults with the same condition
have a much lower cure rate. Chronic lymphocytic leukemia (CLL) is an adult disease with a very
high response rate to treatment and long survival. About a third or more cases of acute myelogenous leukemia (AML) are cured. The response rate of chronic myelogenous leukemia (CML) to
therapy is greater than 90%, and recent major treatment advances have resulted in long-lasting
disease regressions. To date, cures of CML have been documented only after bone marrow
transplantation. However, recent progress with targeted drug therapy has been so impressive
that some experts are hoping that cures will be possible with these agents only (although this is
still quite speculative).
These statistics were entirely different forty years ago. There were no cures of AML or adult ALL,
and the cure rate of childhood ALL was very low. Five year survival of CML was less than half the
present rate, and for CLL about 20% lower. The ability to cure and produce these dramatic
advances in treatment was the result of intense basic research into molecular mechanisms of
leukemic cells, which resulted in effective drug development, eventually culminating in breakthrough clinical trials. The development of bone marrow transplantation (Nobel Prize to Dr. E.
Donnell Thomas), first as a rescue technique and later for certain high risk cases, played an
important role as well. The evolution of the acute leukemias from nearly hopeless to potentially
curable diseases, and the impressive improvement in survivals for the chronic leukemias, are
testimonies to scientific persistence and illustrate the important transition from basic research to
clinical trials to the bedside.
4
leukemia.
Genetic studies on the
marrow were abnormal indicating an
unfavorable outlook, perhaps a few
months at best.
At age 86 there were very few options.
She was too elderly to endure highly
aggressive treatment, yet she had
everything to live for. The situation
seemed hopeless until her son discovered on the internet that Tower Cancer
Research Foundation had a clinical trial
designed especially for elderly individuals with acute leukemia. By this time
bruising and transfusions had started,
and her white blood count was very low
creating a serious risk for infection. The
disease was moving rapidly.
Her attitude nevertheless remained
positive. Lucy enrolled in the Tower
clinical trial with reasonable expectations. She understood that this trial
was a form of research, and the
outcome of a new treatment could not
be predicted. She had nothing to lose
by trying, and no matter the outcome, it
would please her to know that her case
might make a contribution to medical
science. Further, she felt “exceedingly
comfortable and trusting at Tower”, and
bonded with her doctor, many of the
nurses, and especially the research
coordinator who organized and
monitored her treatment.
Eight months have passed since the
start of Lucy’s therapy. This constitutes
almost three times the survival expectancy initially predicted. Although life
definitely is more complicated now, with
frequent treatments and constant monitoring of blood counts, she dutifully
complies, always accompanied by one
of her sons. Her situation is proceeding well enough that she has resumed
walking several miles daily and may be
permitted soon to return to the gym.
One has the impression that with this
positive response to the clinical trial
and her personal drive and energy,
Lucy will log many more miles.
Advantages of Participating
In a Clinical Trial
Patients diagnosed with a serious disease such as cancer are understandably preoccupied with many concerns. Perhaps the last thing that they may wish to be confronted with is a recommendation to participate in a clinical trial with
all the intimidation and surrounding buzz words such as being a “guinea pig” those trials imply. It turns out that, for
a variety of reasons, in the United States only 3% of adults with malignant disease participate in trials, in contrast to
Europe where the figure is close to 20%.
This is unfortunate for a number of reasons:
1) The status quo will never improve unless new therapies are investigated. Cancer
care in the US will become stagnant without adequate numbers of trial participants
to facilitate the development and testing of novel agents.
2) Some patients may benefit more from the innovative treatments available only in
a clinical trial than from the usual standard of care. Unfortunately, many of these
individuals are never offered the chance to participate.
3) There is good reason to believe that patients in clinical trials actually receive
enhanced medical care because of all the extra attention required, since research
physicians and nurses/data coordinators all contribute to the management team.
Peter J. Rosen, MD
M e d i c a l D i re c t o r
4) Many individuals are indeed altruistic and would like part of their life’s legacy to
be that their participation in a trial furthered the science of medicine and led to
better therapy for future patients.
Clinical trials may be offered to the patient at any stage of their disease. Why? Because there is continued room for
improvement in almost every aspect of cancer management. Although great progress has been made there is still
much to be learned and clinical trials are the only way to improve our current state of knowledge. Finally, it should
be emphasized that no approved clinical trial ever offers patients anything less than the accepted standard of
care!
TCRF Names Clinical Trials Program
Tower Cancer Research Foundation is pleased to announce the naming
of its clinical trials program. It will be renamed as a tribute to Frank E.
Rosenfelt (shown right), an individual who played an important role in
its establishment. Frank Rosenfelt was an entertainment industry
attorney, first at RKO, and later rising through the ranks of MGM to
become general counsel and eventually president and CEO in 1972. His
ten years as studio chief were exceedingly successful, and after leaving
MGM he continued to work elsewhere in prestigious positions. He
developed close friendships with a large number of important individuals
in the industry, who held him in very high regard. As a result of this
network and the Rosenfelt family’s deep commitment to cancer research,
significant philanthropic contributions have been made to TCRF. This
support has enabled the Foundation to double its clinical trials activity in
just the past two years. TCRF is honored to name our clinical trials
program The Frank E. Rosenfelt Drug Development program.
Frank E. Rosenfelt
5
Foundation News
From the Director of Administration, Pam Blattner
We have spent a busy summer in preparation for launching some new programs and initiatives
events this fall. Just a few of these are listed below:
• Our second annual Spirit of Hope Luncheon, to be held on Monday, October 20th, will honor
prominent local community members and long time friends of TCRF (see article, p.7).
• The annual holiday breakfast for patients is scheduled for December 4th at Neiman Marcus.
This feel good event is newly renamed “Judy’s Popover Breakfast” in memory of our beloved
founding Board member, the late Judy Ruderman.
• We have finalized the website design and are in the programming stage. It is anticipated that
it will be up and running in October.
We have expanded our patient support programs to include free acupressure workshops and
have reinstituted our free public lecture series. The first was held in June on prostate cancer and the next is in the planning phase.
As a reflection of our rapidly growing clinical trials program, particularly Phase 1 and Phase 2 studies, we have recently welcomed
Dr. Peter Lee as our Associate Medical Director. Because these trials require increased medical oversight and are much more
demanding in terms of patient care, we have also added three new research nurses, Deanna Black, RN; Jessie Conley, RN; and
Eryn Ferdman, CCRC.
As always, many thanks to the donors who have made our expanding programs and services possible.
Notes from the Chairman of the Board
Tower Cancer Research Foundation is becoming the model for a progressive, responsive and
innovative 21st century foundation. We are able
to provide clinical trials and community outreach
in new and innovative ways without losing sight
of how to care for patients. This year alone, our
volunteers, physicians, research nurses and
support staff have come up with more new
ideas, clinical trials, and outreach programs
than any other time in our history. Here are
some of the things we are doing.
This fall, our vastly improved website will be operational. It promises to be very
user friendly and it will ultimately provide our community with information that is
meaningful and informative. The Frank E. Rosenfelt Drug Development Program
has deepened its collaborations with major research institutions such as The City
of Hope, and TGen. Because of the time and support of the Rosenfelt family we
have been able to expand the heart and core of our Foundation’s clinical trials.
We will inaugurate the Ronnie Lippin Cancer Information & Resource Line this
Fall to help those searching for information and referrals while dealing with a
cancer diagnosis.
It has been a year of great accomplishments, but we must not stop here. “Siempre
Adelante” With your help and support, we can move forward.
6
GOING GREEN
In an effort to help the environment, TCRF is joining the green
movement and offering our quarterly newsletter electronically.
If you wish to receive our future
newsletters electronically please
contact Sarah Watters with your
email address at (310) 205-5768
or [email protected].
Please Join Us for Our
Spirit of Hope Luncheon on October 20th
Stacy D. Phillips,
author and certified Family Law
Specialist, who has been named one of
the “Top 75 Female Litigators in California” by the Daily Journal for the
past four years, will be receiving the
Spirit of Hope Award. Stacy, managing
partner of Phillips, Lerner, Lauzon & Jamra, LLP, is also
among an elite group of attorneys named “Best of the
Bar” by the LA Business Journal and one of “LA’s Best
Lawyers” by LA Times’ West Magazine. Stacy and her
family are thrilled to be able to give back to Tower after
her mother was successfully treated for breast cancer
several years ago.
Nancy Kipper,
will receive the inaugural Tower of
Support Award in recognition of
being a caregiver for her daughter,
Sheryl Weissberg, when Sheryl
struggled with Non-Hodgkins
Lymphoma several years ago.
Nancy is a native of Los Angeles and has been
active in and recognized for her contributions to
numerous community non profit organizations,
including Cedars-Sinai and City of Hope, for many
years.
The featured speaker for the luncheon will be Ruth Peltason, author of I Am Not My Breast Cancer, a
compendium of excerpts from a web chat for women diagnosed with breast cancer. Ruth, is a breast cancer survivor, and her book covers topics such as image, intimacy, work and family issues, and is a comfort to any woman
living with breast cancer.
There will also be a pre-holiday boutique with vendors selling purses, jewelry, children’s items and home goods.
If you have not received an invitation and would like to attend, please contact FTA Events, 310-288-1755.
TCRF Tree of Life
Thank you to all of our donors who have contributed since March 2008.
Every donation is meaningful and aids in our exploration of new treatment
options for those fighting cancer and blood disorders. We greatly appreciate
your continued support and generosity. Although we would like to publicly
acknowledge every gift, due to space limitations, we are only able to list
those donations of $1000 or more. Additionally, we engrave a leaf of our
Tree of Life for donations of $2500 or more. Contributions of $2500-$4999
are engreaved on a copper leaf, $5000-$9999 on a gold leaf and $10,000 +
on a platinum leaf. For more information regarding contributions please
contact Pam Blattner at 310-285-7242.
Barbara Meepos and Associates
Bonnie and Barrett Bearson
Bloom Hergott Diemer Rosenthal
LaViolette & Feldman LLP
John Chernin & Family
Mimi and Raymond Diller
Feintech Family Foundation
Sylvia Firestone
Judith Frankel - Menlo Foundation
Friars Charitable Foundation
Madeline Gussman
Randall Katz - Katz Family Foundation
Kara Klein and David Hurwitz
Martha and Dr. Jack Matloff
Al Merschen - Myriad Marketing
Cheryl and Harry Nadjarian
Ben Nickoll -Armstrong Nickoll Family Fdtn.
Milton T. and Rosemary Okun
Steven Paul
Joe Rosen
Nina Rosenthal
Rebecca and Dr. Brett Roth
Loren Rothschild
Dr. Esther Sinclair
Stern Family Foundation
Harry Sherr and Cynthia Strauss
7
Tower Cancer
Research Foundation
PRSRT STD
US Postage
PAID
Los Angeles, CA
Permit #3344
310-285-7242 | www.towercancerfoundatin.org
Administrative Offices:
9229 Wilshire Blvd | Beverly Hills, CA | 90210
Clinical Services:
9090 Wilshire Blvd | Ste 200 | Beverly Hills, CA | 90211
OFFICERS
Steven Lee Yamshon, PhD, Chairman
Solomon Hamburg, MD, PhD, President
Fred Rosenfelt, MD, VP Scientific Affairs
Steve Smith, Treasurer
Abby Levy, Secretary
David Ruderman, Chairman Emeritus
BOARD OF DIRECTORS
Wayne Baruch
Elizabeth Drucker
Julie Dunhill, MD
Barbara Federman, Esq.
David Hoffman, MD
Randy Katz
Alan D. Levy
Sally Magaram
Philomena McAndrew, MD
Sandra D. Miller
Jack Mishkin
Nancy Mishkin
Chris Rose, MD
Rick Rosen
Barry Rosenbloom, MD
Saul Rosenzweig
Heather Shuemaker
James Shuemaker
Deborah Smith
Steve Smith
MEDICAL DIRECTOR
Peter J. Rosen, MD
ASSOCIATE MEDICAL DIRECTOR
Peter Lee, MD, PhD
MEDICAL ADVISORS
Robert Decker, MD
Julie Dunhill, MD
Leland Green, MD
Solomon Hamburg, MD, PhD
David Hoffman, MD
Philomena McAndrew, MD
Dorothy Park, MD
Sepehr Rokhsar, MD
Barry Rosenbloom, MD
Fred Rosenfelt, MD
RESEARCH STAFF
Marie Fuerst, MS, RN
Director of Clinical Research Services
Pam Blattner, MBA
Director of Administration
David Rosenbaum, MD
Director of Education
Newsletter Editor-in-Chief
RESEARCH COORDINATORS
Linda Ford, PA-C
Deanna Black, RN
Jessie Conley, RN, BS
Cheryl Elzinga
Eryn Ferdman, CCRC
Elizabeth Tran, CCRC
8
ADMINISTRATIVE ASSISTANTS
Tiwana Broom-Harvey
Dorothy Parker
Sarah Watters
Announcements
Ronnie Lippin Cancer
Information & Resource Line
Launches October 13th
877-RLC-2120 - www.LaCancerInfo.org
2008 Spirit of Hope Luncheon
October 20th - Beverly Hills Hotel
Your Support is Appreciated
Tower Cancer Research Foundation is a non-profit research foundation,
dedicated to providing state of the art cutting edge clinical research in a private
practice setting. We believe that patients are thereby treated in a more caring
environment, while retaining the same physician and nursing team throughout
their illnesses. We are committed to this concept and to the continued expansion of these capabilities. In addition, our close affiliation with the City of Hope allows us
to access additional trials previously only available at that institution. Although many of our
trials receive funding from pharmaceutical companies, these monies are insufficient to
support the extensive infrastructure required. Therefore, we depend on outside contributions to continue to advance the cause of cancer research. Your tax deductible donation to
Tower Cancer Research Foundation may be mailed directly to our office, or via our web site
(www.towercancerfoundation.org).
President, Tower Cancer Research Foundation
MISSION STATEMENT
Tower Cancer Research Foundation is committed to providing innovative research,
community education and caring patient support while developing more effective treatments for cancer and blood disorders.